Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P07384
UPID:
CAN1_HUMAN
Alternative names:
Calcium-activated neutral proteinase 1; Calpain mu-type; Calpain-1 large subunit; Cell proliferation-inducing gene 30 protein; Micromolar-calpain
Alternative UPACC:
P07384; Q2TTR0; Q6DHV4
Background:
Calpain-1 catalytic subunit, also known as Calcium-activated neutral proteinase 1, plays a pivotal role in cytoskeletal remodeling and signal transduction by catalyzing the proteolysis of substrates. This enzyme is regulated by calcium and is involved in the cleavage of CTBP1 and activation of caspase-7, highlighting its critical function in cellular processes.
Therapeutic significance:
The association of Calpain-1 with Spastic paraplegia 76, an autosomal recessive neurodegenerative disorder, underscores its potential as a therapeutic target. Understanding the role of Calpain-1 could open doors to potential therapeutic strategies for managing symptoms and slowing the progression of this debilitating condition.